الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 140 |  |  |
| | | from | 140 | | |
Abstract
Breast cancer is the most diagnosed cancer in women worldwide and more initiatives are directed towards early diagnosis and treatment to reduce mortality and improve quality of life. Anthracycline drugs are used as adjuvant chemotherapy after surgical intervention. Despite their potency, their use is limited because of their cardiotoxic effects. The higher the cumulative dose the higher the chance of developing cardiomyopathy. There is no sufficient data regarding the impact of anthracycline on the right ventricle despite the ongoing research on their effect on the left ventricle. In our study, we enrolled 40 newly diagnosed breast cancer female patients in Ismailia Oncology Hospital and Suez Canal University Hospital, who were planned to receive anthracycline-contained regimen (37 patients received doxorubicin and 3 patients received epirubicin) for 4 cycles. By using 2D echocardiography, we assessed right ventricular systolic function including RVFAC, TAPSE, RV systolic S’ velocity, and RVGLS. In addition, we assessed LV EF by using modified Simpson’s method together with MAPSE, medial and lateral S’ velocities. We measured the change in these parameters after three and six months during anthracycline chemotherapy. We found statistically significant subclinical right ventricular dysfunction with DROP of RVGLS during the follow up period (p value <0.05). Moreover, total anthracycline cumulative dose was an independent predictor of right ventricular